Candel Therapeutics, Inc. (CADL)
Free
No email, no account, no signup.
Pulling latest news for Candel Therapeutics, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Cancer immunotherapy development
Market Cap
$200M
We're already tracking Candel Therapeutics, Inc. — here are the latest events we've registered
Recent News
- In November 2024, Candel Therapeutics received FDA Orphan Drug Designation for its lead candidate, CAN-2409, for the treatment of pancreatic cancer. This follows positive interim Phase 2 results released earlier in the year showing significant survival benefits in patients. The company has also previously secured FDA Fast Track Designation for this program.
Want to know how this news affects Candel Therapeutics, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Candel Therapeutics, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.